Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference : CME Request for Credit Survey

Thank you for attending the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference. The AACR is accredited by the ACCME to provide continuing medical education for physicians. The AACR designates this live activity for a maximum of 23.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Request for Credit
To receive CME Credit you must complete the following Request for Credit Survey. A credit certificate (for physicians) or certificate of attendance (for non physician attendees) will only be issued to those who complete the survey. Your certificate will be sent by email after the survey is completed.

Question Title

* 1. Contact Information

First Name

Last Name

Question Title

* 2. Please enter your AACR ID number (If you don't have one, please leave blank)

Question Title

* 3. Address Information

Address

Address 2

City/Town

State

ZIP

Country

Question Title

* 4. Please indicate your email address

APPROVED SESSIONS WORKSHEET PDF: If you don't remember which sessions you attended, please access the following link to the Sessions Worksheet PDF: Joint Immunotherapy CME Sessions Worksheet

Question Title

* 5. Number of Credits Claimed

Question Title

* 6. Select One

Physician

Non Physician

Question Title

* 7. Which statement best describes your practice setting?

Laboratory Research only

Clinical Practice only

Clinical Practice and Laboratory Research

Administration

Other (please specify)

Question Title

* 8. Please rate your scope of knowledge in Cancer Immunotherapy prior to participating in this CME activity.

	Little Knowledge	Some Knowledge	Moderate Knowledge	Above Average Knowledge	Extensive Knowledge
Knowledge Level	Knowledge Level Little Knowledge	Knowledge Level Some Knowledge	Knowledge Level Moderate Knowledge	Knowledge Level Above Average Knowledge	Knowledge Level Extensive Knowledge

Question Title

* 9. Activity included opportunity to learn interactively from faculty/participants?

	Strongly Agree	Agree	Neutral	Disagree	Strongly Disagree
Please rate	Please rate Strongly Agree	Please rate Agree	Please rate Neutral	Please rate Disagree	Please rate Strongly Disagree

Question Title

* 10. Content covered was useful and relevant to my practice?

	Strongly Agree	Agree	Neutral	Disagree	Strongly Disagree
Please rate	Please rate Strongly Agree	Please rate Agree	Please rate Neutral	Please rate Disagree	Please rate Strongly Disagree

Question Title

* 11. To what extent were the learning objectives met by this CME activity?

	Strongly Agree	Agree	Neutral	Disagree	Strongly Disagree
Describe the principles of cancer immunotherapy, the value of combination therapy, and mechanisms of new immunotherapy drugs.	Describe the principles of cancer immunotherapy, the value of combination therapy, and mechanisms of new immunotherapy drugs. Strongly Agree	Describe the principles of cancer immunotherapy, the value of combination therapy, and mechanisms of new immunotherapy drugs. Agree	Describe the principles of cancer immunotherapy, the value of combination therapy, and mechanisms of new immunotherapy drugs. Neutral	Describe the principles of cancer immunotherapy, the value of combination therapy, and mechanisms of new immunotherapy drugs. Disagree	Describe the principles of cancer immunotherapy, the value of combination therapy, and mechanisms of new immunotherapy drugs. Strongly Disagree
Articulate how checkpoint blockade is being used in a therapeutic setting.	Articulate how checkpoint blockade is being used in a therapeutic setting. Strongly Agree	Articulate how checkpoint blockade is being used in a therapeutic setting. Agree	Articulate how checkpoint blockade is being used in a therapeutic setting. Neutral	Articulate how checkpoint blockade is being used in a therapeutic setting. Disagree	Articulate how checkpoint blockade is being used in a therapeutic setting. Strongly Disagree
Assess the contribution of the tumor microenvironment, cancer cell metabolism, and the microbiome in tumor progression, immunosuppression, and growth.	Assess the contribution of the tumor microenvironment, cancer cell metabolism, and the microbiome in tumor progression, immunosuppression, and growth. Strongly Agree	Assess the contribution of the tumor microenvironment, cancer cell metabolism, and the microbiome in tumor progression, immunosuppression, and growth. Agree	Assess the contribution of the tumor microenvironment, cancer cell metabolism, and the microbiome in tumor progression, immunosuppression, and growth. Neutral	Assess the contribution of the tumor microenvironment, cancer cell metabolism, and the microbiome in tumor progression, immunosuppression, and growth. Disagree	Assess the contribution of the tumor microenvironment, cancer cell metabolism, and the microbiome in tumor progression, immunosuppression, and growth. Strongly Disagree
Articulate how recent advances in genetic engineering are contributing to personalized cancer immunotherapy.	Articulate how recent advances in genetic engineering are contributing to personalized cancer immunotherapy. Strongly Agree	Articulate how recent advances in genetic engineering are contributing to personalized cancer immunotherapy. Agree	Articulate how recent advances in genetic engineering are contributing to personalized cancer immunotherapy. Neutral	Articulate how recent advances in genetic engineering are contributing to personalized cancer immunotherapy. Disagree	Articulate how recent advances in genetic engineering are contributing to personalized cancer immunotherapy. Strongly Disagree
Identify mechanisms involved in the biology of vaccination.	Identify mechanisms involved in the biology of vaccination. Strongly Agree	Identify mechanisms involved in the biology of vaccination. Agree	Identify mechanisms involved in the biology of vaccination. Neutral	Identify mechanisms involved in the biology of vaccination. Disagree	Identify mechanisms involved in the biology of vaccination. Strongly Disagree
Evaluate genomic methods for identifying tumor antigens and predicting response to immunotherapy.	Evaluate genomic methods for identifying tumor antigens and predicting response to immunotherapy. Strongly Agree	Evaluate genomic methods for identifying tumor antigens and predicting response to immunotherapy. Agree	Evaluate genomic methods for identifying tumor antigens and predicting response to immunotherapy. Neutral	Evaluate genomic methods for identifying tumor antigens and predicting response to immunotherapy. Disagree	Evaluate genomic methods for identifying tumor antigens and predicting response to immunotherapy. Strongly Disagree
Utilize technology to aid in cancer cell characterization and immunotherapy.	Utilize technology to aid in cancer cell characterization and immunotherapy. Strongly Agree	Utilize technology to aid in cancer cell characterization and immunotherapy. Agree	Utilize technology to aid in cancer cell characterization and immunotherapy. Neutral	Utilize technology to aid in cancer cell characterization and immunotherapy. Disagree	Utilize technology to aid in cancer cell characterization and immunotherapy. Strongly Disagree

Question Title

* 12. The speakers presented sufficient scientific evidence to support the content presented?

	Strongly Agree	Agree	Neutral	Disagree	Strongly Disagree
Please rate	Please rate Strongly Agree	Please rate Agree	Please rate Neutral	Please rate Disagree	Please rate Strongly Disagree

Question Title

* 13. Meeting Presentations were free from commercial influence or bias?

	Strongly Agree	Agree	Neutral	Disagree	Strongly Disagree
Please rate	Please rate Strongly Agree	Please rate Agree	Please rate Neutral	Please rate Disagree	Please rate Strongly Disagree

Question Title

* 14. Please rate how likely you are to make changes in your practice in the following areas:

	Strongly Agree	Agree	Neutral	Disagree	Strongly Disagree
Incorporate new knowledge of the contributions of laboratory research to drug development and patient care, as well as the epidemiological implications of cancer incidence and mortality.	Incorporate new knowledge of the contributions of laboratory research to drug development and patient care, as well as the epidemiological implications of cancer incidence and mortality. Strongly Agree	Incorporate new knowledge of the contributions of laboratory research to drug development and patient care, as well as the epidemiological implications of cancer incidence and mortality. Agree	Incorporate new knowledge of the contributions of laboratory research to drug development and patient care, as well as the epidemiological implications of cancer incidence and mortality. Neutral	Incorporate new knowledge of the contributions of laboratory research to drug development and patient care, as well as the epidemiological implications of cancer incidence and mortality. Disagree	Incorporate new knowledge of the contributions of laboratory research to drug development and patient care, as well as the epidemiological implications of cancer incidence and mortality. Strongly Disagree
Incorporate critical concepts, related skills, and/or methods associated with basic cancer research into the clinical practice of oncology to aid in the detection, diagnosis, treatment, and prevention of cancer.	Incorporate critical concepts, related skills, and/or methods associated with basic cancer research into the clinical practice of oncology to aid in the detection, diagnosis, treatment, and prevention of cancer. Strongly Agree	Incorporate critical concepts, related skills, and/or methods associated with basic cancer research into the clinical practice of oncology to aid in the detection, diagnosis, treatment, and prevention of cancer. Agree	Incorporate critical concepts, related skills, and/or methods associated with basic cancer research into the clinical practice of oncology to aid in the detection, diagnosis, treatment, and prevention of cancer. Neutral	Incorporate critical concepts, related skills, and/or methods associated with basic cancer research into the clinical practice of oncology to aid in the detection, diagnosis, treatment, and prevention of cancer. Disagree	Incorporate critical concepts, related skills, and/or methods associated with basic cancer research into the clinical practice of oncology to aid in the detection, diagnosis, treatment, and prevention of cancer. Strongly Disagree
Refine clinical research design and protocols that improve patient outcomes.	Refine clinical research design and protocols that improve patient outcomes. Strongly Agree	Refine clinical research design and protocols that improve patient outcomes. Agree	Refine clinical research design and protocols that improve patient outcomes. Neutral	Refine clinical research design and protocols that improve patient outcomes. Disagree	Refine clinical research design and protocols that improve patient outcomes. Strongly Disagree
Develop new interdisciplinary collaborations to advance the progress of cancer research from “bench to bedside and back” yielding further improvements in patient outcomes.	Develop new interdisciplinary collaborations to advance the progress of cancer research from “bench to bedside and back” yielding further improvements in patient outcomes. Strongly Agree	Develop new interdisciplinary collaborations to advance the progress of cancer research from “bench to bedside and back” yielding further improvements in patient outcomes. Agree	Develop new interdisciplinary collaborations to advance the progress of cancer research from “bench to bedside and back” yielding further improvements in patient outcomes. Neutral	Develop new interdisciplinary collaborations to advance the progress of cancer research from “bench to bedside and back” yielding further improvements in patient outcomes. Disagree	Develop new interdisciplinary collaborations to advance the progress of cancer research from “bench to bedside and back” yielding further improvements in patient outcomes. Strongly Disagree

Question Title

* 15. As a result of your participation in the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference, what are you going to do differently? Please indicate any changes to your practice:

Question Title

* 16. Please indicate any barriers you perceive in implementing changes to your practice (check all that apply).

Cost

Reimbursement/insurance issues

Lack of experience

Patient compliance issues

Lack of opportunity (patients)

Lack of resources (equipment)

Guidelines

Lack of administrative support

Lack of time to assess/counsel patients

No barriers

Other (please specify)

Question Title

* 17. Please rate your scope of knowledge in Cancer Immunotherapy after participating in this CME activity.

	Little Knowledge	Some Knowledge	Moderate Knowledge	Above Average Knowledge	Extensive Knowledge
Knowledge Level	Knowledge Level Little Knowledge	Knowledge Level Some Knowledge	Knowledge Level Moderate Knowledge	Knowledge Level Above Average Knowledge	Knowledge Level Extensive Knowledge

Question Title

* 18. Please provide any additional comments or suggestions for use in planning future AACR CME activities.

Thank you for your participation in the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference. Your certificate will be processed soon and sent by email.